Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study

EORTC health-related quality of life (HRQOL) measures were maintained during treatment with trastuzumab deruxtecan (T-DXd) and with trastuzumab emtansine (T-DM1) among patients with HER2-positive metastatic breast cancer, according to patient-reported outcomes from the DESTINY-Breast03 trial. Patients receiving T-DXd demonstrated favorable prespecified variables such as pain compared with those receiving T-DM1, and median time to first hospitalization was three times longer with T-DXd versus T-DM1.